Literature DB >> 6561068

Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor.

Q W Ye, M B Mokyr, J M Pyle, S Dray.   

Abstract

We had shown previously that progression of MOPC-315 plasmacytoma growth is associated with an increase in the percentage of macrophages in the spleen as well as a decrease in the ability of tumor-bearer spleen cells to mount an antitumor cytotoxic response upon in vitro immunization. Here we provide evidence that macrophages in the MOPC-315 tumor-bearer spleen are responsible at least in part for the suppression of the generation of antitumor cytotoxicity. Accordingly, removal of most macrophages by depletion of phagocytic cells or Sephadex G-10-adherent cells from spleens of mice bearing a large tumor resulted in augmented antitumor immune potential. Also, Sephadex G-10-adherent spleen cells from tumor-bearing (but not normal) mice drastically suppressed the in vitro generation of antitumor cytotoxicity by normal spleen cells. The suppressive activity of these adherent cells did not reside in contaminating suppressor T cells, since it was not reduced by treatment with monoclonal anti-Thy 1.2 antibody plus complement. The Sephadex G-10-adherent cell population from the tumor-bearer spleen suppressed the in vitro generation of antitumor cytotoxicity against autochthonous tumor cells but not against allogeneic EL4 tumor cells, and hence the suppression was apparently specific. The suppressive activity of the Sephadex G-10-adherent cell population from tumor-bearer spleens was overcome by treatment of the tumor-bearing mice with a low curative dose of cyclophosphamide. This immunomodulatory effect of a low dose of the drug in overcoming the suppression mediated by the Sephadex G-10-adherent cell population enables the effector arm of the immune system of tumor-bearing mice to cooperate effectively with the drug's tumoricidal activity in tumor eradication.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6561068     DOI: 10.1007/bf00205423

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

1.  Role of macrophages in the tumor-induced suppression of mitogen responses in rats.

Authors:  A M Kruisbeek; M van Hees
Journal:  J Natl Cancer Inst       Date:  1977-06       Impact factor: 13.506

Review 2.  Suppressor cells: permitters and promoters of malignancy?

Authors:  D Naor
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

Review 3.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

4.  Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages.

Authors:  K D Elgert; W L Farrar
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

5.  Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.

Authors:  C C Ting; D Rodrigues
Journal:  J Natl Cancer Inst       Date:  1982-10       Impact factor: 13.506

6.  Macrophage-like suppressor cells in rats. II. Evidence for a quantitative rather than a qualitative change in tumour-bearer animals.

Authors:  P J Webb; C G Brooks; R W Baldwin
Journal:  Cell Immunol       Date:  1980-07-01       Impact factor: 4.868

7.  Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.

Authors:  M B Mokyr; D P Braun; S Dray
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

8.  Inhibition of in vitro lymphoproliferative responses to tumor-associated antigens by suppressor cells from rats bearing progressively growing Gross leukemia virus-induced tumors.

Authors:  M Glaser; H Kirchner; R B Herberman
Journal:  Int J Cancer       Date:  1975-09-15       Impact factor: 7.396

9.  Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. II. Mechanisms for induction of suppression.

Authors:  C C Ting; M E Hargrove
Journal:  J Natl Cancer Inst       Date:  1982-10       Impact factor: 13.506

10.  The peritoneal exudate lymphocyte. I. Differences in antigen responsiveness between peritoneal exudate and lymph node lymphocytes from immunized guinea pigs.

Authors:  D L Rosenstreich; J T Blake; A S Rosenthal
Journal:  J Exp Med       Date:  1971-11-01       Impact factor: 14.307

View more
  9 in total

1.  Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.

Authors:  S Shoval; R Ophir; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Inhibitors of lymphocyte activation secreted by human melanoma cell lines.

Authors:  D Giacomoni; S Ben-Efraim; F Najmabadi; S Dray
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 4.  Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Authors:  P Goedegebuure; J B Mitchem; M R Porembka; M C B Tan; B A Belt; A Wang-Gillam; W E Gillanders; W G Hawkins; D C Linehan
Journal:  Curr Cancer Drug Targets       Date:  2011-07       Impact factor: 3.428

5.  Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.

Authors:  J A Wise; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.

Authors:  L Gorelik; A Prokhorova; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

8.  Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients.

Authors:  M Eura; T Maehara; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 9.  Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy.

Authors:  S Dray; M B Mokyr
Journal:  Med Oncol Tumor Pharmacother       Date:  1989
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.